<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225614</url>
  </required_header>
  <id_info>
    <org_study_id>P081221</org_study_id>
    <secondary_id>2009-A01023-54 (IDRCB)</secondary_id>
    <nct_id>NCT01225614</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive</brief_title>
  <acronym>DYVINE</acronym>
  <official_title>Study of Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults With Myotonic Dystrophy Type 1(DM1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Française contre les Myopathies (AFM), Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter randomized controlled open labeled study testing efficacy and tolerance&#xD;
      of early launching of night non invasive ventilation in patients with myotonic dystrophy type&#xD;
      1(DM1). The object of this project is to estimate the effects of the early introduction of&#xD;
      non invasive ventilation on the arisen of complication (non expected hospitalization,&#xD;
      tracheostomy even death) with regard to a simple respiratory follow-up in patients affected&#xD;
      by myotonic dystrophy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DM1 is the most frequent genetic myopathy in the adult. Actually there is no curative&#xD;
      treatment, and symptomatic cares are essentials. The respiratory impairment is the main cause&#xD;
      of morbid-mortality at these patients. The median of survival of the patients affected by DM1&#xD;
      with respiratory failure is of 59 years. Mechanisms of disease are complex implying a central&#xD;
      and a direct impairment of respiratory muscles. These patients can present an alveolar&#xD;
      hypoventilation, notably during night, not correlated to the muscular weakness. These&#xD;
      patients often present a cognitive impairment complicating the interpretation of the clinical&#xD;
      symptoms and their compliance to treatments. International recommendations for launching&#xD;
      mechanical ventilation in neuromuscular diseases are the presence: 1) at least a clinical&#xD;
      sign of alveolar hypoventilation, and one of the following criteria 2) diurnal hypercapnia (&gt;&#xD;
      45 mmHg), 3) restrictive syndrome (vital capacity &lt; 50 % and\or maximal inspiratory pressure&#xD;
      &lt; 60 cmH20), 4) the existence of a oxygen night-desaturation (SaO2 &lt; 88 %) of more than 5&#xD;
      minutes. However, a Cochrane meta analyzes underline the absence of randomised study&#xD;
      estimating the profit risk in the long term of the night-mechanical ventilation for&#xD;
      progressive myopathies such as the DM1. The validity of these criteria and the effect of the&#xD;
      ventilation on the survival and the complications were never estimated in DM1. On a&#xD;
      retrospective series, the compliance is inferior and the observance is only 20 % a year and&#xD;
      the incidence of the complications (death or resort to a tracheostomy) was 6 times as&#xD;
      important in non observant patients.&#xD;
&#xD;
      Objective (s) of the clinical study To estimate the efficiency and the tolerance of long term&#xD;
      night-non invasive mechanical ventilation in patients affected by DM1.&#xD;
&#xD;
      Main judgment criteria:&#xD;
&#xD;
      Mortality and non programmed hospitalization.&#xD;
&#xD;
      Experimental plan:&#xD;
&#xD;
      Multicenter, national, randomized, controlled, study on 2 parallel groups. The subjects&#xD;
      presenting a theoretical indication following consensual criteria of ventilation will be&#xD;
      randomized either for a start up of ventilation or for an annual monitoring.&#xD;
&#xD;
      Hypothesis: Early starting of non invasive ventilation allows a reduction of 20 % of the&#xD;
      mortality or the number of non-programmed hospitalization compared to the control group for&#xD;
      which the rate would be 40 %.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients having a complication (number of non expected hospitalization or death) at 5 years.</measure>
    <time_frame>5 YEARS</time_frame>
    <description>Rate of patients having a complication (number of non expected hospitalization or death) at 5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of survival between the randomisation at 5 years</measure>
    <time_frame>5 YEARS</time_frame>
    <description>Distribution of survival between the randomisation at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients having a formal indication of ventilation</measure>
    <time_frame>5 YEARS</time_frame>
    <description>Number of patients having a formal indication of ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of tracheostomized patients at 5 years</measure>
    <time_frame>5 YEARS</time_frame>
    <description>Number of tracheostomized patients at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non expected hospitalizations at 5 years</measure>
    <time_frame>5 YEARS</time_frame>
    <description>Number of non expected hospitalizations at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observance of the ventilation defined by an average minimal use of 4 am by 12:00 pm .</measure>
    <time_frame>5 YEARS</time_frame>
    <description>Observance of the ventilation defined by an average minimal use of 4 am by 12:00 pm (determined in a objective way by the counter of the device).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of respiratory and sleep impairment at 5 years</measure>
    <time_frame>5 YEARS</time_frame>
    <description>Degree of respiratory and sleep impairment at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life SF36, scales of depression</measure>
    <time_frame>5 YEARS</time_frame>
    <description>Quality of life SF36, scales of depression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Myopathy</condition>
  <condition>Muscular Weakness</condition>
  <condition>Respiratory Insufficiency</condition>
  <arm_group>
    <arm_group_label>bipap ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care and ventilation if occurrence of absolute criteria of ventilation (cf infra).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bilevel pressure ventilator</intervention_name>
    <description>Nocturnal home ventilation</description>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_label>bipap ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman of age ≥ 18 years&#xD;
&#xD;
          -  Preliminary medical examination&#xD;
&#xD;
          -  Enlightened and written consent&#xD;
&#xD;
          -  Genetically proved Steinert disease&#xD;
&#xD;
               1. Presenting at least one of the following 3 criteria&#xD;
&#xD;
                    -  A hypercapnia: PaCO2 &gt; 45 mmHg or&#xD;
&#xD;
                    -  A night-desaturation: SaO2 &lt; 88 % more than consecutive 5 minutes or&#xD;
&#xD;
                    -  Apnea syndrome with significant sleep:index of apnea / hypopnea&gt; a 30 / hour&#xD;
&#xD;
               2. And with presence of at least a clinical sign: dyspnoea, orthopnea, headaches,&#xD;
                  asthenia, diurnal sleepiness, or any other sign suggestive of disturbance of the&#xD;
                  sleep or of respiratory dysfunction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age inferior to 18&#xD;
&#xD;
          -  Regime of legal protection&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Absolute indication for ventilation: clinical signs (dyspnoea, orthopnea, headaches,&#xD;
             asthenia, diurnal sleepiness), AND PaCO2 &gt; 60 mmHg, AND night-desaturation &lt; 88 % AND&#xD;
             one CV &lt; 50 % of the theoretical or the PIMAX &lt; 60 cm H2O&#xD;
&#xD;
          -  Acute respiratory failure&#xD;
&#xD;
          -  Already ventilated patient&#xD;
&#xD;
          -  Patient under oxygen&#xD;
&#xD;
          -  Not (beneficiary to a regime of Social Security or legal successor)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DAVID ORLIKOWSKI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Home ventilation unit and intensive care, centre of neuromuscular disease (Garches Mondor Necker Hendaye), Raymond Poincaré hospital Versailles Saint Quentin University.</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Home ventilation</keyword>
  <keyword>Myotonic dystrophy type 1 (DM1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

